吉非替尼对晚期肺腺癌患者疗效及与皮疹的相关性

The relationship between skin rash and gefitinib and clinical outcome for patients of advanced lung adenocarcinoma

目的:分析晚期肺腺癌患者使用吉非替尼后其疗效及与皮疹之间的相关性。方法:对我院自2009年1月至2012年1月收治的56例晚期肺腺癌患者使用吉非替尼后出现的不良反应进行分析,比较皮疹与疗效之间关系。结果:使用吉非替尼后,皮疹、肝功能异常、胃肠道反应及急性间质性肺炎的发生率分别为44.6%、32.1%、17.9%及7.1%。与未出现皮疹患者相比较,使用吉非替尼出现皮疹的患者,其客观有效率明显升高(P<0.01)。结论:使用吉非替尼后出现皮疹的患者其客观有效率较未出现皮疹患者高。

Objective：We analyzed clinical course of lung adenocarcinoma and assessed the relation between skin rash and efficacy of gefitinib. Methods：Between January 2009 and January 2012, We analyzed adverse events of 56 lung cancer patients administered gefitinib and assessed the relation between skin rash and efficacy of gefitinib. Re- suits：In all 56 cases,skin trouble developed in 44.6% ,liver damage occurred in 32.1% ,diarrhea in 17.9% and a- cute lung injury in 7.1%. The ORR of skin rash was superior to those without skin rash （P 〈0.01 ）. Conclusion： The objective response among the patients with skin rash was significantly superior to the patients without skin rash.